Novo Nordisk failed to disclose £7.8m in payments to doctors and others over three years
BMJ 2024; 386 doi: https://doi.org/10.1136/bmj.q1511 (Published 08 July 2024) Cite this as: BMJ 2024;386:q1511Linked Opinion
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
- Elisabeth Mahase
- The BMJ
Drug company Novo Nordisk has been reprimanded by the UK pharmaceutical regulator after it admitted failing to disclose around £7.8m in payments to 150 recipients including doctors, patients, journalists, and healthcare organisations over a three year period.12
In a voluntary admission Novo Nordisk informed the Prescription Medicines Code of Practice Authority (PMCPA) that between 2020 and 2022 it had failed to disclose around 500 payments because of problems with its vendor tagging system. PMCPA is the self-regulatory body that administers the Association of the British Pharmaceutical Industry’s (ABPI) code of …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£33 / $40 / €36 (excludes VAT)
You can download a PDF version for your personal record.